Nasal Chondrocyte-Tissue Engineered Cartilage (N-TEC)
By 2026, the Phase II "Nose2Knee" clinical trials have validated the nose as a superior source for joint repair.
Nasal Septum Advantage: Cells from the nasal septum (nasal chondrocytes) have a much higher and more consistent regenerative capacity than those harvested from the knee.
Maturation Success: The 2026 trial results showed that N-TEC (matured in a lab for several weeks) resulted in superior tissue integration and clinical outcomes compared to undifferentiated cell matrices.
Scaling: This technology is now being used for larger defects ($2.7$ to $6.0$ $cm^2$) and revision surgeries where previous treatments like microfracture failed.
2 Views